Helvia. Repositorio Institucional de la Universidad de Córdoba
Publication
Artículo científico (JournalArticle)
Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms
Context: Pituitary neuroendocrine tumors (PitNETs) are a commonly underestimated pathology in
terms of incidence and associated morbimortality. Currently, an appreciable subset of patients are
resistant or poorly responsive to the main current medical treatments [i.e., synthetic somatostatin
analogs (SSAs) and dopamine agonists]. Thus, development and optimization of novel and available
medical therapies is necessary. Biguanides (metformin, buformin, and phenformin) are antidiabetic
drugs that exert antitumoral actions in several tumor types, but their pharmacological effects on
PitNETs are poorly known.
Objective: We aimed to explore the direct effects of biguanides on key functions (cell viability,
hormone release, apoptosis, and signaling pathways) in primary cell cultures from human PitNETs
and cell lines. Additionally, we evaluated the effect of combined metformin with SSAs on cell
viability and hormone secretion.
Design: A total of 13 corticotropinomas, 13 somatotropinomas, 13 nonfunctioning PitNETs, 3
prolactinomas, and 2 tumoral pituitary cell lines (AtT-20 and GH3) were used to evaluate the direct
effects of biguanides on cell viability, hormone release, apoptosis, and signaling pathways.
Results: Biguanides reduced cell viability in all PitNETs and cell lines (with phenformin being the
most effective biguanide) and increased apoptosis in somatotropinomas. Moreover, buformin and
phenformin, but not metformin, reduced hormone secretion in a cell type–specific manner.
Combination metformin/SSA therapy did not increase SSA monotherapy effectiveness. Effects of
biguanides on PitNETs could involve the modulation of AMP-activated protein kinase–dependent
([Ca21]i, PI3K/Akt) and independent (MAPK) mechanisms.
Conclusion: Altogether, our data unveil clear antitumoral effects of biguanides on PitNET cells,
opening avenues to explore their potential as drugs to treat these pathologies. (J Clin Endocrinol
Metab 104: 3501–3513, 2019)
Project:
AEI / Programa Estatal de I+D+I Orientado a los Retos de la Sociedad BFU2016-80360-R
,
MICINN / Programa Estatal de I+D+I Orientada a los Retos de la Sociedad FJCI-2016-30825
,
MINECO / Programa Estatal de I+D+I Orientada a los Retos de la Sociedad PI16
,
MINECO CP15
,
Junta de Andalucía CTS-1406
,
Junta de Andalucía BIO-0139
View at: http://hdl.handle.net/10396/35488